The news comes days after Novo cut its full-year outlook due to rising competition from copycat compounders, and named a new ...

Health-care companies fell as investors continued to retreat from formerly hot areas such as obesity-drug and vaccine makers. Shares of Novo Nordisk continued their slide despite reporting a ...

As announced July 29, Novo Nordisk NVO saw 18% sales growth and 40% operating profit growth at constant currencies in the ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Novo Nordisk stock wavered after its second-quarter earnings report early Wednesday as it vowed to cut costs amid ...

Hims & Hers is a top telehealth stock with strong revenue growth, innovative offerings, and long-term potential. Click here ...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.

Shares of Prothena climbed after Novo Nordisk said during its second-quarter earnings call that it expects to advance a treatment for amyloidosis it bought from Prothena in 2021. The Dublin company's ...

In this week’s edition of InnovationRx, we look at a biotech entrepreneur treating a rare genetic disease, new tech aimed at ...

With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect ...

Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.